Evidence map›Paper›PMID 33864242›Full record

ArticleClinical and experimental immunology2021

Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice.

Gaetane Nocturne, Bineta Ly, Audrey Paoletti, Juliette Pascaud, Raphaele Seror, Carole Nicco, Fabienne Mackay, F B Vincent, Thierry Lazure, Sophie Ferlicot and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Current status of BAFF targeting immunotherapy in B-cell neoplasm.International journal of clinical oncology · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Gaetane NocturneDepartment of Rheumatology, FHU CARE, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.ORCID 0000-0001-6809-0733
Bineta LyINSERM, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
Audrey PaolettiINSERM, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
Juliette PascaudINSERM, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
Raphaele SerorDepartment of Rheumatology, FHU CARE, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
Carole NiccoCochin Institute, INSERM, University Paris Descartes, Paris, France.
Fabienne MackayQIMR Berghofer Medical Research Institute in Brisbane QLD, Herston, QLD, Australia.
F B VincentRheumatology Research Group, Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
Thierry LazureDepartment of Pathology, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
Sophie FerlicotDepartment of Pathology, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
Lev StimmerUS27 Platform for Experimental Pathology, Molecular Imaging Research Center, INSERM-CEA, Fontenay-aux-Roses, France.
Quentin PascalUS27 Platform for Experimental Pathology, Molecular Imaging Research Center, INSERM-CEA, Fontenay-aux-Roses, France.
Sandrine RoullandAix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.
Roman KrzysiekDepartment of Immunology, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
Salima Hacein-BeyDepartment of Immunology, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
Frederic BatteuxCochin Institute, INSERM, University Paris Descartes, Paris, France.
Xavier MarietteDepartment of Rheumatology, FHU CARE, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
Inserm · FRAssistance Publique – Hôpitaux de Paris · FRCentre National de la Recherche Scientifique · FRMonash Health · AUQIMR Berghofer Medical Research Institute · AU

Funding

ANR 10-LABX-LERMITFondation pour la Recherche Médicale DEQ20150934719PfizerSociété Française de rhumatologie
6 · The paper itself

Abstract

The impact of treatment on the risk of lymphoma in patients with rheumatoid arthritis (RA) is unclear. Here, we aimed to assess if the risk of lymphoma differs according to the type of tumor necrosis factor inhibitor (TNFi), comparing monoclonal anti-TNF antibodies to the soluble TNF receptor. We used B cell activating factor belonging to the TNF family (BAFF)-transgenic (Tg) mice as a model of autoimmunity-associated lymphoma. Six-month-old BAFF-Tg mice were treated with TNFi for 12 months. Histological examination of the spleen, assessment of the cellular composition of the spleen by flow cytometry and assessment of B cell clonality were performed at euthanasia. Crude mortality and incidence of lymphoma were significantly higher in mice treated with monoclonal anti-TNF antibodies compared to both controls and mice treated with the soluble TNF receptor, even at a high dose. Flow cytometry analysis revealed decreased splenic macrophage infiltration in mice treated with monoclonal anti-TNF antibodies. Overall, this study demonstrates, for the first time, that a very prolonged treatment with monoclonal anti-TNF antibodies increase the risk of lymphoma in B cell-driven autoimmunity. These data suggest a closer monitoring for lymphoma development in patients suffering from B cell-driven autoimmune disease with long-term exposure to monoclonal anti-TNF antibodies.

Indexed as

AnimalsAntibodies, MonoclonalArthritis, RheumatoidAutoimmune DiseasesAutoimmunityB-Cell Activating FactorB-LymphocytesCell LineLymphomaMiceMice, Inbred C57BLMice, TransgenicSpleenTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsAntibodies, MonoclonalB-Cell Activating FactorTnfsf13b protein, mouseTumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitorsanti-TNFautoimmunityBAFFlymphomamacrophages

Identifiers

PMID33864242
PMCPMC8274188
OpenAlexW3152644203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.